Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–28 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Factor X Deficiency Clear all

Completed Phase 3 Interventional Results available

A Study Investigating Treatment Factor X in People With Factor X Deficiency

NCT00930176

View directory record Official record

Conditions: Factor X Deficiency
Interventions: Human Coagulation FACTOR X; Biological
Lead sponsor: Bio Products Laboratory; Other
Eligibility: 12 Years and older

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: San Francisco, California • Indianapolis, Indiana • New York, New York

Source: ClinicalTrials.gov public record

Updated Dec 11, 2014 · Synced May 21, 2026, 6:22 PM EDT

Completed No phase listed Observational

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery

NCT03161626

View directory record Official record

Conditions: Factor 10 Deficiency
Interventions: Coagadex; Drug
Lead sponsor: Bio Products Laboratory; Other
Eligibility: 12 Years and older

Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Gainesville, Florida • New Orleans, Louisiana • Kalamazoo, Michigan

Source: ClinicalTrials.gov public record

Updated Nov 11, 2021 · Synced May 21, 2026, 6:22 PM EDT

Completed Phase 2 Interventional Results available

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

NCT02163577

View directory record Official record

Conditions: X-linked Hypophosphatemia
Interventions: burosumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 5 Years to 12 Years

Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 1 more

Source: ClinicalTrials.gov public record

Updated May 5, 2024 · Synced May 21, 2026, 6:22 PM EDT

Terminated Phase 1Phase 2 Interventional

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

NCT00076557

View directory record Official record

Conditions: Hemophilia B
Interventions: Adeno-Associated Viral with Human Factor IX; Genetic
Lead sponsor: Avigen; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Apr 3, 2007 · Synced May 21, 2026, 6:22 PM EDT